Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency
DSpace/Manakin Repository
Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency
| Title: | Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency |
| Author: |
Wassenberg, Tessa; Molero-Luis, Marta; Jeltsch, Kathrin; Hoffmann, Georg F.; Assmann, Birgit; Blau, Nenad; Garcia-Cazorla, Angeles; Artuch, Rafael; Pons, Roser; Pearson, Toni S.; Leuzzi, Vincenco; Mastrangelo, Mario; Pearl, Phillip L.; Lee, Wang Tso; Kurian, Manju A.; Heales, Simon; Flint, Lisa; Verbeek, Marcel; Willemsen, Michèl; Opladen, Thomas
Note: Order does not necessarily reflect citation order of authors. |
| Citation: | Wassenberg, T., M. Molero-Luis, K. Jeltsch, G. F. Hoffmann, B. Assmann, N. Blau, A. Garcia-Cazorla, et al. 2017. “Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency.” Orphanet Journal of Rare Diseases 12 (1): 12. doi:10.1186/s13023-016-0522-z. http://dx.doi.org/10.1186/s13023-016-0522-z. |
| Full Text & Related Files: |
5241937.pdf (1.105Mb; PDF) 
|
| Abstract: | Aromatic L-amino acid decarboxylase deficiency (AADCD) is a rare, autosomal recessive neurometabolic disorder that leads to a severe combined deficiency of serotonin, dopamine, norepinephrine and epinephrine. Onset is early in life, and key clinical symptoms are hypotonia, movement disorders (oculogyric crisis, dystonia, and hypokinesia), developmental delay, and autonomic symptoms. In this consensus guideline, representatives of the International Working Group on Neurotransmitter Related Disorders (iNTD) and patient representatives evaluated all available evidence for diagnosis and treatment of AADCD and made recommendations using SIGN and GRADE methodology. In the face of limited definitive evidence, we constructed practical recommendations on clinical diagnosis, laboratory diagnosis, imaging and electroencephalograpy, medical treatments and non-medical treatments. Furthermore, we identified topics for further research. We believe this guideline will improve the care for AADCD patients around the world whilst promoting general awareness of this rare disease. Electronic supplementary material The online version of this article (doi:10.1186/s13023-016-0522-z) contains supplementary material, which is available to authorized users. |
| Published Version: | doi:10.1186/s13023-016-0522-z |
| Other Sources: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/pdf/ |
| Terms of Use: | This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
| Citable link to this page: | http://nrs.harvard.edu/urn-3:HUL.InstRepos:30370959 |
| Downloads of this work: |
This item appears in the following Collection(s)
-
HMS Scholarly Articles [19985]
Contact administrator regarding this item (to report mistakes or request changes)
